公开(公告)号：US11701440B2

公开(公告)日：2023-07-18

申请号：US17047859

申请日：2019-04-15

申请人： NIHON MEDI-PHYSICS CO., LTD. ,  National University Corporation Kagoshima University ,  National University Corporation Chiba University

发明人： Shota Komoto ,  Yu Ogawa ,  Yoshinari Shoyama ,  Tadashi Hatano ,  Yuji Ito ,  Yasushi Arano ,  Hiroyuki Suzuki ,  Tomoya Uehara

IPC分类号： A61K47/68 ,  A61K51/10 ,  C07K5/065 ,  C07K5/087 ,  A61K51/04 ,  A61K51/08 ,  C07D257/02 ,  C07K7/08 ,  C07K16/32

CPC分类号： A61K51/1093 ,  A61K47/6887 ,  A61K47/6889 ,  A61K51/0482 ,  A61K51/088 ,  A61K51/1096 ,  C07D257/02 ,  C07K5/06078 ,  C07K5/0812 ,  C07K7/08 ,  C07K16/32 ,  C07K2317/21

摘要： Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

公开(公告)号：US11167050B2

公开(公告)日：2021-11-09

申请号：US16648703

申请日：2018-09-26

申请人： NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY

发明人： Yasushi Arano ,  Tomoya Uehara ,  Hiroyuki Suzuki

IPC分类号： A61K51/08 ,  A61K51/04 ,  C07K5/087 ,  A61K51/10

摘要： Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

公开(公告)号：US20190091353A1

公开(公告)日：2019-03-28

申请号：US16081141

申请日：2017-02-28

申请人： National University Corporation Chiba University

发明人： Yasushi Arano ,  Tomoya Uehara

IPC分类号： A61K51/10 ,  A61K51/04 ,  A61K47/12

摘要： The present invention relates to a compound, etc. capable of providing a radiolabeled drug that can reduce the renal accumulation thereof in the early stage after the administration thereof. [1] A compound, etc. represented by the formula (1), [2] a compound, etc. containing the compound, etc. according to the item [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound, etc. containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound, etc. according to the item [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound, etc. according to the item [1] or [2], [5] use of the compound, etc. according to the item [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound, etc. according to the item [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound, etc. according to the item [3]:

公开(公告)号：US10960089B2

公开(公告)日：2021-03-30

申请号：US16081141

申请日：2017-02-28

申请人： NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY

发明人： Yasushi Arano ,  Tomoya Uehara

IPC分类号： A61K51/08 ,  A61K51/10 ,  C07K5/08 ,  C07K5/083 ,  A61K47/12 ,  A61K51/04 ,  A61P25/00

摘要： Described are: [1] a compound represented by the formula (1), [2] a compound containing the compound according to [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound according to [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound according to [1] or [2], [5] use of the compound according to [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound according to [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound according to [3]: